T cell receptors for mesothelin cancer immunotherapy

The USPTO granted patent US12595290B2 to Fred Hutchinson Cancer Center covering binding proteins (T cell receptors) specific for mesothelin peptides Msln20-28 and Msln530-538, along with compositions and recombinant host cells for cancer immunotherapy. The patent protects methods for treating mesothelioma, pancreatic cancer, ovarian cancer, and lung cancer using these binding proteins.

BIG3-PHB2 Interaction-Inhibiting Peptide Therapeutic Agent for Breast Cancer

USPTO granted patent US12595289B2 to Tokushima University for a therapeutic peptide that inhibits BIG3-PHB2 protein interaction, designed specifically for treating estrogen receptor-positive breast cancer. The peptide selectively targets BIG3-overexpressing cancer cells while avoiding expression of side effects. The patent covers 6 claims including the peptide composition and pharmaceutical formulation.

Anti-follicle stimulating hormone receptor antibodies and methods of treatment

USPTO granted Patent US12595293B2 to The Wistar Institute covering isolated antibodies and antigen-binding fragments that specifically bind to Follicle Stimulating Hormone Receptor (FSHR), along with methods for treating diseases by administering these antibodies. The patent includes 14 claims and covers compositions for cancer treatment applications.

Dosing regimes for treatment of synucleinopathies

USPTO granted patent US12595295B2 to Prothena Biosciences Limited covering antibody dosing regimes for treatment of synucleinopathies. The patent specifies intravenous antibody dosing of 3000-5000 mg or 1300-1700 mg every 3-5 weeks. This grant provides exclusive intellectual property rights for these therapeutic dosing protocols.

Fluorine-containing compound and anti-cancer medical use thereof

The USPTO granted patent US12595275B2 to Ascentawits Pharmaceuticals, Ltd. on April 7, 2026, covering a fluorine-containing compound (Formula II/III) with anti-cancer medical applications. The patent claims novel structures incorporating trifluoromethyl groups and fluorine-substituted aryl or heteroaryl groups at specific positions, with 17 total claims.

Aminopyridine compound as aldehyde trapping agent

USPTO granted Patent US12595259B2 to Zhuhai United Laboratories Co., Ltd. for an aminopyridine compound functioning as an aldehyde trapping agent, including formula (I) and its pharmaceutically acceptable salts. The patent covers 18 claims and has applications in ophthalmic therapeutics.

Substituted pyrimidine radical quenchers, Arizona State University

Substituted pyrimidine radical quenchers, Arizona State University

Amidines and amidine analogs for bacterial infection treatment

The USPTO granted Patent US12595251B2 to Georgia State University Research Foundation, covering amidine compounds and methods for treating bacterial infections or potentiating antibiotics. The patent names Binghe Wang, David W. Boykin, Manjusha Roy Choudhary, Arvind Kumar, Bingchen Yu, and Mengyuan Zhu as inventors. The patent, with 10 claims, covers CPC classifications including C07D compounds and A61P 31/04 (anti-infectives).

IV LEAGUE trademark opposition, Council Ivy Group Presidents v. IV League Key West

The USPTO Trademark Trial and Appeal Board accepted filing of Opposition No. TTAB91306391 by the Council of Ivy Group Presidents against IV League Key West's application for the IV LEAGUE mark. The opposition challenges registration on likelihood of confusion and/or dilution grounds. Both parties are now bound by TTAB procedural rules and deadlines.

Ponderosa Farm & Outdoor Opposition - Pitchfork Enterprises v. Wannberg

Pitchfork Enterprises, LLC filed an opposition proceeding (TTAB91306392) against the trademark application for PONDEROSA FARM & OUTDOOR by applicants Timothy E. Wannberg and Mariah Day Wannberg. The opposition was filed and accepted by the USPTO Trademark Trial and Appeal Board on April 6, 2026, challenging the registration of the mark.